(Q44611831)

4 December 2017

title

Prevalence, pathogenesis, and impact of atrial fibrillation (English)

1 reference

4 December 2017

1 reference

Cynthia A Sanoski

1

1 reference

4 December 2017

publication date

1 May 2010

1 reference

American Journal of Health-System Pharmacy

4 December 2017

published in

1 reference

4 December 2017

volume

67

1 reference

4 December 2017

issue

9 Suppl 5

1 reference

4 December 2017

page(s)

S11-6

1 reference

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Increasing prevalence of atrial fibrillation and flutter in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Obesity and the Risk of New-Onset Atrial Fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Validation of Clinical Classification Schemes for Predicting Stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Atrial fibrillation and heart failure: treatment considerations for a dual epidemic.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left V

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Incident atrial fibrillation and mortality in older adults with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Changing trends of hospital utilization in patients after their first episode of atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

Cost of atrial fibrillation in United States managed care organizations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100148

31 March 2020

Identifiers

DOI

10.2146/AJHP100148

1 reference

4 December 2017

1 reference